GLP‐1: physiological effects and potential therapeutic applications
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Glucagon‐like peptide 1 (GLP‐1) is a gut‐derived incretin hormone with the potential to change diabetes. The physiological effects of GLP‐1 are multiple, and many seem to ameliorate the different conditions defining the diverse physiopathology seen in type 2 diabetes. In animal studies, GLP‐1 stimulates β‐cell proliferation and neogenesis and inhibits β‐cell apoptosis. In humans, GLP‐1 stimulates insulin secretion and inhibits glucagon and gastrointestinal secretions and motility. It enhances satiety and reduces food intake and has beneficial effects on cardiovascular function and endothelial dysfunction. Enhancing incretin action for therapeutic use includes GLP‐1 receptor agonists resistant to degradation (incretin mimetics) and dipeptidyl peptidase (DPP)‐4 inhibitors. In clinical trials with type 2 diabetic patients on various oral antidiabetic regimes, both treatment modalities efficaciously improve glycaemic control and β‐cell function. Whereas the incretin mimetics induce weight loss, the DPP‐4 inhibitors are considered weight neutral. In type 1 diabetes, treatment with GLP‐1 shows promising effects. However, several areas need clinical confirmation: the durability of the weight loss, the ability to preserve functional β‐cell mass and the applicability in other than type 2 diabetes. As such, long‐term studies and studies with cardiovascular end‐points are needed to confirm the true benefits of these new classes of antidiabetic drugs in the treatment of diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
Self-citationBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Cited by
Current anti-diabetic agents and their molecular targets: A review
Kerru, N., Singh-Pillay, A., Awolade, P., & Singh, P. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.061 · Cited by 369
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
“org, the pattern of J Clin Endocrinol Metab, January 2012, 97(1):121–131 jcem.”
BackgroundInfluentialNovel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
“In addition to their known benefits for patients with T2DM [14,20,28], GLP-1 receptor agonists have also shown promising effects in the treatment of type 1 diabetes mellitus (T1DM).”
BackgroundInfluentialBello, N. T., Kemm, M. H., Ofeldt, E. M., & Moran, T. H. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00275.2010 · Cited by 66
Metadata
- Authors
- Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2008-10-14
- Volume
- 10
- Issue
- 11
- Pages
- 994-1003
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2085770128
- Cited by
- 95
- References
- 40
- FWCI
- 6.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP‐1: physiological effects and potential therapeutic applications. https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.00853.x
- The paper
- Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008). GLP‐1: physiological effects and potential therapeutic applications. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.00853.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.